Skip to main content

Antiviral peptides blocking herpes simplex virus type 1 entry into cells

Objective

The objective is to produce anti-herpes simplex virus type 1 (HSV-1) peptide pharmaceuticals that lock entry of HSV-1 into target cells. Preliminary data have identified several putative lead peptides, but using viral mutagenesis, synthesis of overlapping peptides from each of four HSV-1 surface glycoproteins, a set of lead peptides will results. The latter will be modified by modern peptide pharmaceutical procedures to improve their "activity-stability-delivery" profiles. Both in vitro and in vivo assays will be used to rank activity of these modified peptides. It is proposed natural and modified anti-herpes peptides will be used alone or in combination with nucleoside anti-herpes pharmaceuticals to reduce infection times, overcome resistant strains and alleviate the more severe HSV-1 symptoms such as pain, blindness and herpes encephalitis.

Call for proposal

Data not available

Coordinator

CENTRO INTERUNIVERSITARIO DI RICERCA SUI PEPTI DI BIOATTIVI
Address
Via Mezzocannone 8
80134 Napoli
Italy

See on map

Links

Participants (3)

FUNDACAO CALOUSTE GULBENKIAN
Portugal
Address
Rua Da Quinta Grande N6
2780-156 Oeiras

See on map

Links
PRIMM SRL
Italy
Address
Via Olgettina 58
20132 Milano

See on map

Links
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
Address
Tennis Court Road
CB2 1QP Cambridge

See on map

Links